The short version of freeze-dried powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-26 and is reviewed periodically as new material appears.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
The first reference to Israel in non-biblical sources is found in the Merneptah Stele in c. 1209 BCE. The inscription is very brief and says: "Israel is laid waste and his seed is not". The inscription refers to a people, not an individual or nation state, who inhabit central Palestine or the highlands of Samaria. Some Egyptologists suggest that Israel appeared in earlier topographical reliefs, dating to the Eighteenth Dynasty or Nineteenth Dynasty (i.e. reign of Ramesses II) , but this reading remains controversial. In the Hebrew Bible, Israel first appears in Genesis 32:29, where an angel renames Jacob to Israel after Jacob fought with him. According to the folk etymology given in the text, Israel is derived from yisra, "to prevail over" or "to struggle with", and El, a Canaanite-Mesopotamian creator god that is tenuously identified with Yahweh. However, modern scholarship interprets El as the subject, "El rules/struggles", from sarar (שָׂרַר) 'to rule' (cognate with sar (שַׂר) 'ruler', Akkadian šarru 'ruler, king'), which is likely cognate with the similar root sara (שׂרה) "fought, strove, contended". Dr. Tzemah Yoreh clarifies that Israel is a combination of 'to strive with' (ש.ר.ה) and 'God' (אל) and that Jacob's name alternates between Jacob and Israel in the biblical narrative, even after his renaming, due to the authors having different opinions about Jacob's moral character. The gradual ethnonymic shift from "Israelites" to "Jews", regardless of their descent from Judah is made explicit in the Book of Esther (4th century BCE) of the Tanakh.
In October, a two-day demonstration in Reggio by some 40,000 northern CGIL metalworkers, supported the revolt. The Reggio revolt was one of the most controversial periods in the history of Calabria, partly because of the absence of related documentation, which was often destroyed or hidden. Historiography generally reflects the perspective of the author. Examples:
=== Domestic === The January 2026 escalation was cited by Danish prime minister Mette Frederiksen as a factor behind her decision to call snap elections, stating that "We must define our relationship with the U.S. We must arm ourselves to ensure peace on our continent. We must keep Europe together". Opinion polls indicated that the crisis boosted the popularity of Frederiksen's party, the Social Democrats.
Sources: en.wikipedia.org
A launch failure on 21 April 1964 in which the U.S. Transit-5BN-3 navigation satellite failed to achieve orbit and burned up on re-entry north of Madagascar. The 17,000 Ci (630 TBq) plutonium metal fuel in its SNAP-9a RTG was ejected into the atmosphere over the Southern Hemisphere where it burned up, and traces of plutonium-238 were detected in the area a few months later. This incident resulted in the NASA Safety Committee requiring intact reentry in future RTG launches, which in turn impacted the design of RTGs in the pipeline. The Nimbus B-1 weather satellite, whose launch vehicle was deliberately destroyed shortly after launch on 21 May 1968 because of erratic trajectory. Launched from the Vandenberg Air Force Base, its SNAP-19 RTG containing relatively inert plutonium dioxide was recovered intact from the seabed in the Santa Barbara Channel five months later and no environmental contamination was detected. In 1969 the launch of the first Lunokhod lunar rover mission failed, spreading polonium-210 over a large area of Russia. The failure of the Apollo 13 mission in April 1970 meant that the Lunar Module reentered the atmosphere carrying an RTG and burned up over Fiji. It carried a SNAP-27 RTG containing 44,500 Ci (1,650 TBq) of plutonium dioxide in a graphite cask on the lander leg which survived reentry into the Earth's atmosphere intact, as it was designed to do, the trajectory being arranged so that it would plunge into 6–9 kilometers of water in the Tonga trench in the Pacific Ocean.
The dimerization reaction is unselective. By-products include acetaldehyde (due to isomerization). The selectivity and speed of dimerization can be increased by adding a catalyst, such as platinum, platinum-palladium, or iodine with sulfolane. 2-methyl-1,3-dioxolane is formed as a side product in the last case.
== External links == GeneReviews/NCBI/NIH/UW entry on Maple Syrup Urine Disease Branched+Chain+Ketoacid+Dehydrogenase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 1.2.4.4 [1]
Sources: en.wikipedia.org
Elizabeth Broadbent; Keith J Petrie; Jodie Main; John Weinman (2006). "The brief illness perception questionnaire". Journal of Psychosomatic Research. 60 (6): 631–637. doi:10.1016/j.jpsychores.2005.10.020. PMID 16731240. Wikidata Q50936509. Elizabeth Broadbent; Carissa Wilkes; Heidi Koschwanez; John Weinman; Sam Norton; Keith J Petrie (2015). "A systematic review and meta-analysis of the Brief Illness Perception Questionnaire". Psychology & Health. 30 (11): 1361–1385. doi:10.1080/08870446.2015.1070851. PMID 26181764. Wikidata Q38548518. E. Broadbent; R. Stafford; B. MacDonald (2009). "Acceptance of Healthcare Robots for the Older Population: Review and Future Directions". International journal of social robotics. 1 (4): 319–330. doi:10.1007/s12369-009-0030-6. Wikidata Q115258302. Hayley Robinson; Bruce Macdonald; Ngaire Kerse; Elizabeth Broadbent (2013). "The psychosocial effects of a companion robot: a randomized controlled trial". Journal of the American Medical Directors Association. 14 (9): 661–667. doi:10.1016/j.jamda.2013.02.007. PMID 23545466. Wikidata Q45166572. Elizabeth Broadbent; Liesje Donkin; Julia C Stroh (2011). "Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients". Diabetes Care. 34 (2): 338–340. doi:10.2337/dc10-1779. PMC 3024345. PMID 21270191. Wikidata Q34507111.
==== Starch granules ==== Starch granules are very common in chloroplasts, typically taking up 15% of the organelle's volume, though in some other plastids like amyloplasts, they can be big enough to distort the shape of the organelle. Starch granules are simply accumulations of starch in the stroma, and are not bounded by a membrane. Starch granules appear and grow throughout the day, as the chloroplast synthesizes sugars, and are consumed at night to fuel respiration and continue sugar export into the phloem, though in mature chloroplasts, it is rare for a starch granule to be completely consumed or for a new granule to accumulate. Starch granules vary in composition and location across different chloroplast lineages. In red algae, starch granules are found in the cytoplasm rather than in the chloroplast. In C4 plants, mesophyll chloroplasts, which do not synthesize sugars, lack starch granules.
Usually made for promotional purposes, it is closer to an advertisement than a classic documentary. Modern lightweight digital video cameras and computer-based editing have greatly aided documentary makers, as has the dramatic drop in equipment prices. The first film to take full advantage of this change was Martin Kunert and Eric Manes' Voices of Iraq, where 150 DV cameras were sent to Iraq during the war and passed out to Iraqis to record themselves.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.